Article

Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical Study

2024-11-29

Abstract excerpt

<h4>Introduction</h4> Clinical trials do not typically assess underlying molecular mechanisms of vaccine immunogenicity or reactogenicity. We evaluated the reactogenicity and immunogenicity of 4 mRNA vaccines and potential contributing mechanisms and identified shared and unique clinical and immunologic features. <h4>Methods</h4> This ongoing open-label, phase 1 trial randomized healthy adults (18-75 years) to rec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4fa500c3-e661-5e94-a7b2-970e68162a17
DOI: 10.1101/2024.11.26.24318005

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Shared Clinical and Immunologic Features of mRNA Vaccines: Preliminary Results from a Comparative Clinical StudyDOI 10.1101/2024.11.26.24318005Read

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccinesSemantic proximity Read

mRNA Vaccine Technology Beyond COVID-19Semantic proximity Read

Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized TrialSemantic proximity Read

sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical modelsSemantic proximity Read

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity Read

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesSemantic proximity Read

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine LandscapeSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity Read

Current Developments and Challenges of mRNA VaccinesSemantic proximity Read

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read